New drug ATG 022 targets Hard-to-Treat cancers in early trial
NCT ID NCT05718895
First seen Apr 22, 2026 · Last updated May 18, 2026 · Updated 7 times
Summary
This early-phase study tests a new drug called ATG 022 in 156 adults with advanced or spreading solid tumors that no longer respond to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or slow their growth. The study is currently recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, China
Contact Email: •••••@•••••
Contact
-
Beijing GoBroad Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
Contact
-
Cabrini Health Limited
RECRUITINGMalvern, Australia
Contact Email: •••••@•••••
Contact
-
Cancer Research SA Pty Ltd
COMPLETEDAdelaide, Australia
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Email: •••••@•••••
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
Contact
Contact Email: •••••@•••••
Contact
-
Gansu provincial cancer hospital [recruiting]
RECRUITINGLanzhou, China
Contact Email: •••••@•••••
Contact
-
General Hospital of Ningxia Medical University
RECRUITINGYinchuan, China
Contact Email: •••••@•••••
Contact
-
Hubei Cancer Hospital
RECRUITINGWuhan, China
Contact Email: •••••@•••••
Contact
-
Integrated Clinical Oncology Network Pty Ltd (Icon)
RECRUITINGSouth Brisbane, Australia
Contact
Contact Email: •••••@•••••
-
Jinan Central Hospital
RECRUITINGJinan, China
Contact Email: •••••@•••••
Contact
-
Liaoning Cancer Hospital
RECRUITINGShenyang, China
Contact Email: •••••@•••••
Contact
-
Shanxi provincial cancer hospital
RECRUITINGTaiyuan, China
Contact Email: •••••@•••••
Contact
-
The Affiliated Hospital of Qingdao University
RECRUITINGQingdao, China
Contact Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, China
Contact Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Zhenghzou University
RECRUITINGZhengzhou, China
Contact Email: •••••@•••••
Contact
-
The First affiliated hospital of Xi'An Jiao Tong Ubiversity
RECRUITINGXi'an, China
Contact Email: •••••@•••••
Contact
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiangzhuang, China
Contact Email: •••••@•••••
Contact
-
Tianjin Medical Universuty Cancer Institute & Hospital
RECRUITINGTianjin, China
Contact Email: •••••@•••••
Contact
-
Tongren Hospital Shanghai
RECRUITINGShanghai, China
Contact Email: •••••@•••••
Contact
-
West China Hospital, Sichuan University
RECRUITINGChengdu, China
Contact
Contact Email: •••••@•••••
Contact
-
Xuzhou Central Hospital
RECRUITINGXuzhou, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.